Discontinued — last reported Q3 '22
Cumulative Gross Losses and Impairments
EquityEli Lilly Cumulative Gross Losses and Impairments decreased by 65.5% to $11.10M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 62.0%, from $29.20M to $11.10M. Over 4 years (FY 2020 to FY 2024), Cumulative Gross Losses and Impairments shows an upward trend with a 204.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
First reportedQ2 2022
Last reportedQ3 2022
Metric ID:
cumulative_gross_losses_and_impairmentsHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.90M | $4.00M | $5.20M | $25.20M | $36.90M | $51.60M | $49.20M | $39.00M | $44.60M | $59.70M | $37.90M | $42.50M | $44.30M | $29.20M | $43.20M | $33.60M | $32.20M | $11.10M |
| QoQ Change | — | +37.9% | +30.0% | +384.6% | +46.4% | +39.8% | -4.7% | -20.7% | +14.4% | +33.9% | -36.5% | +12.1% | +4.2% | -34.1% | +47.9% | -22.2% | -4.2% | -65.5% |
| YoY Change | — | — | — | — | >999% | >999% | +846.2% | +54.8% | +20.9% | +15.7% | -23.0% | +9.0% | -0.7% | -51.1% | +14.0% | -20.9% | -27.3% | -62.0% |
Range$2.90M – $59.70M
CAGR+37.1%
Avg YoY Growth+224.1%
Median YoY Growth+11.5%
Current Streak3 quarters decline
Cumulative Gross Losses and Impairments at Other Companies
Frequently Asked Questions
- What is Eli Lilly's cumulative gross losses and impairments?
- Eli Lilly (LLY) reported cumulative gross losses and impairments of $11.10M in Q3 2025.
- How has Eli Lilly's cumulative gross losses and impairments changed year-over-year?
- Eli Lilly's cumulative gross losses and impairments decreased by 62.0% year-over-year, from $29.20M to $11.10M.
- What is the long-term trend for Eli Lilly's cumulative gross losses and impairments?
- Over 4 years (2020 to 2024), Eli Lilly's cumulative gross losses and impairments has grown at a 204.9% compound annual growth rate (CAGR), from $500.00K to $43.20M.